Corleis, Björn
Hoffmann, Donata http://orcid.org/0000-0003-4552-031X
Rauch, Susanne
Fricke, Charlie http://orcid.org/0000-0001-7493-6627
Roth, Nicole
Gergen, Janina
Kovacikova, Kristina http://orcid.org/0000-0002-6582-222X
Schlottau, Kore http://orcid.org/0000-0002-3999-0393
Halwe, Nico Joel http://orcid.org/0000-0002-7983-2808
Ulrich, Lorenz http://orcid.org/0000-0001-5004-806X
Schön, Jacob
Wernike, Kerstin http://orcid.org/0000-0001-8071-0827
Widera, Marek http://orcid.org/0000-0001-5417-9307
Ciesek, Sandra http://orcid.org/0000-0002-1802-7565
Mueller, Stefan O. http://orcid.org/0000-0001-6549-8936
Mettenleiter, Thomas C. http://orcid.org/0000-0002-8385-7899
Maione, Domenico http://orcid.org/0000-0002-8441-9241
Petsch, Benjamin
Beer, Martin http://orcid.org/0000-0002-0598-5254
Dorhoi, Anca http://orcid.org/0000-0003-1739-749X
Article History
Received: 22 April 2022
Accepted: 15 January 2023
First Online: 13 February 2023
Competing interests
: B.C., B.P., M.B. and A.D. report institutional funding for the work. S.R., N.R., J.G., K.K., S.O.M. and B.P. are employees of CureVac SE, Tübingen, Germany, a publicly listed company developing mRNA-based vaccines and immunotherapeutics. Authors may hold shares in the company. S.R., B.P. and N.R. are inventors on several patents on mRNA vaccination and use thereof. D.M. holds shares in GSK. All other authors declare no conflicts of interest.